Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel-based company engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. While these molecules induce apoptosis (programmed cell death) in mature cells, they spare stem cells. This differential sensitivity is used to improve the outcome of bone marrow transplantation mainly by eliminating severe adverse effects.